All In Biotech

Drug Trial Radar · NCT04447469

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

814

Actual

Start

Jul 28, 2020

Primary completion

Nov 12, 2021

Study completion Jan 14, 2022

Sponsor

Sponsor type
Industry
Collaborators
Kiniksa Pharmaceuticals, Ltd.
First posted
Jun 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

Conditions

  • COVID

Interventions

  • mavrilimumabDrug

    anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])

  • PlaceboOther

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29Time frame: Day 29
  2. Cohort 1, Phase 3: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29Time frame: Day 29
  3. Cohort 2, Phase 2: Percentage of Participants Who Died by Day 29Time frame: Day 29
  4. Cohort 2, Phase 3: Percentage of Participants Who Died by Day 29Time frame: Day 29

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • SHARP Health Care

    San Diego, California

  • Affinity Health

    Chicago, Illinois

  • Tulane University School of Medicine

    New Orleans, Louisiana

  • Allina Health System

    Minneapolis, Minnesota

  • Mercy Clinic Hospitalists

    Springfield, Missouri

  • University of Cincinnati

    Cincinnati, Ohio

  • Bryn Mawr Hospital

    Bryn Mawr, Pennsylvania

  • University of Texas Health Sciences

    Houston, Texas

  • Hospital Adventista de Belem

    Belém, Brazil

  • IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará

    Fortaleza, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José, Brazil

  • Hospital Alemão Oswaldo Cruz

    São Paulo, Brazil

  • Hospital Cardio Pulmonar

    Salvador, Estado de Bahia, Brazil

  • Hospital Luxemburgo - Associação Mário Penna

    Belo Horizonte, Minas Gerais, Brazil

  • CPCLIN - Centro de Pesquisas Clínicas

    Natal, Rio Grande do Norte, Brazil

  • Hospital Bruno Born

    Lajeado, Rio Grande do Sul, Brazil

  • UPECLIN - Unidade de Pesquisa Clínica

    Botucatu, São Paulo, Brazil

  • IPECC - Instituto de Pesquisa Clínica de Campinas

    Campinas, São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

    Ribeirão Preto, São Paulo, Brazil

  • Clinica Las Condes

    Santiago, Chile

  • Hospital Clinico Universidad de Chile

    Santiago, Chile

  • Hospital Nacional Alberto Sabogal Sologuren

    Bellavista, Peru

  • Essalud - Hospital de Emergencias Grau

    Lima Cercado, Peru

  • Hospital Nacional Cayetano Heredia

    San Martín de Porres, Peru

  • Clinica Providencia

    San Miguel, Peru

  • IATROS International

    Bloemfontein, South Africa

  • Tiervlei Trial Center

    Cape Town, South Africa

  • TASK Eden

    George, South Africa

  • Into Research - Little Company of Mary Medical Center

    Pretoria, South Africa

  • Limpopo Clinical Research Initiative

    Rustenburg, South Africa

  • University of Cape Town - Lung Institute

    Cape Town, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.